EXCEED THE SPACE PROVIDED. Vaccination against variola virus (the causative agent of smallpox) is currently accomplished by vaccinia virus. Little is known about 1) the antigens and epitopes targeted by the cellular responses in humans immunized with vaccinia virus, and 2) which responses are crossreactive with variola virus and hence would be expected to contribute to the protection engendered by the vaccine. In the first part of the studies proposed herein, we will 1) determine immunodominant antigens recognized by Class I and Class II restricted responses in humans immunized with vaccinia virus, 2) map the epitopes recognized within each antigen, and 3) determine their degree of crossreactivity with homologous variola virus-derived sequences. We anticipate that these studies will lead to the definition of a broad range of epitopes, facilitate a rigorous definition of correlates of protection against smallpox infection in humans, and also enable the evaluation of the performance of different vaccine candidates. Vaccinia virus is also actively investigated as a potential vaccine delivery vehicle, either alone or in prime/boost regimens, for disease indications such as HIV, malaria and cancer. Thus, it should be noted that identification and characterization of the determinants recognized by humans infected/vaccinated by vaccinia virus would also enable the characterization and optimization of experimental vaccines utilizing vaccinia virus-derived vectors as a delivery system. The vaccinia-based vaccines currently available, while effective, are associated with significant and serious, albeit rare, side effects. Because of these side effects, and because of the worldwide eradication of variola virus, vaccination of the general population was deemed as no longer desirable. Recent renewed concerns have been raised over bioterrorist use of the virus. In the context of the studies proposed herein, a concern could be raised that if the vaccinia-induced protection is mediated by relatively few immunodominant and crossreactive antigens, a modified smallpox virus could be engineered that lacks those crossreactive epitopes. Under this terrifying scenario, the protection elicited by the vaccinia would be ineffective against the biological weapon. In the second part of the grant, we propose to counter this risk through the identification of variola virus-specific determinants derived from immunodominant antigens in the context of the vaccinia virus responses, but not crossreactive with the homologous variola virus sequences. These variola virus-derived epitopes would be incorporated in an optimized multi-determinant vaccine construct, inserted in the currently available vaccinia vaccine. PERFORMANCE SITE ========================================Section End===========================================

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI056268-03
Application #
6837674
Study Section
Special Emphasis Panel (ZRG1-VACC (02))
Program Officer
Challberg, Mark D
Project Start
2003-07-01
Project End
2006-12-31
Budget Start
2005-01-01
Budget End
2005-12-31
Support Year
3
Fiscal Year
2005
Total Cost
$871,202
Indirect Cost
Name
La Jolla Institute
Department
Type
DUNS #
603880287
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Salek-Ardakani, Shahram; Moutaftsi, Magdalini; Crotty, Shane et al. (2008) OX40 drives protective vaccinia virus-specific CD8 T cells. J Immunol 181:7969-76
Oseroff, Carla; Peters, Bjoern; Pasquetto, Valerie et al. (2008) Dissociation between epitope hierarchy and immunoprevalence in CD8 responses to vaccinia virus western reserve. J Immunol 180:7193-202
Assarsson, Erika; Greenbaum, Jason A; Sundstrom, Magnus et al. (2008) Kinetic analysis of a complete poxvirus transcriptome reveals an immediate-early class of genes. Proc Natl Acad Sci U S A 105:2140-5
Benhnia, Mohammed Rafii-El-Idrissi; McCausland, Megan M; Su, Hua-Poo et al. (2008) Redundancy and plasticity of neutralizing antibody responses are cornerstone attributes of the human immune response to the smallpox vaccine. J Virol 82:3751-68
Assarsson, Erika; Sidney, John; Oseroff, Carla et al. (2007) A quantitative analysis of the variables affecting the repertoire of T cell specificities recognized after vaccinia virus infection. J Immunol 178:7890-901
Jing, Lichen; Chong, Tiana M; Byrd, Benjamin et al. (2007) Dominance and diversity in the primary human CD4 T cell response to replication-competent vaccinia virus. J Immunol 178:6374-86
Moutaftsi, Magdalini; Bui, Huynh-Hoa; Peters, Bjoern et al. (2007) Vaccinia virus-specific CD4+ T cell responses target a set of antigens largely distinct from those targeted by CD8+ T cell responses. J Immunol 178:6814-20
Sette, Alessandro; Peters, Bjoern (2007) Immune epitope mapping in the post-genomic era: lessons for vaccine development. Curr Opin Immunol 19:106-10
Tscharke, David C; Woo, Wai-Ping; Sakala, Isaac G et al. (2006) Poxvirus CD8+ T-cell determinants and cross-reactivity in BALB/c mice. J Virol 80:6318-23
Tscharke, David C; Karupiah, Gunasegaran; Zhou, Jie et al. (2005) Identification of poxvirus CD8+ T cell determinants to enable rational design and characterization of smallpox vaccines. J Exp Med 201:95-104

Showing the most recent 10 out of 12 publications